Medigene/SynCore expand marketing partnership for Veregen

Medigene and SynCore Biotechnology Co have expanded the existing exclusive licensing and supply contract into new regions for the supply and marketing of Veregen (sinecatechins 15% ointment) for the treatment of genital warts. Along with existing agreements in Taiwan, SynCore will now be responsible for the approval process and commercialisation of the drug for the treatment of genital warts throughout Asia (excluding China and Korea), Australia and New Zealand. In addition to income from the production and supply of the ointment and the active ingredient, Medigene will receive payment when specific milestones are reached. Medigene already has partnerships in Asia for the distribution of Veregen in China (GC Rise Pharmaceutials) and South Korea (Kolon Pharmaceuticals).

Veregen is already marketed in the US (by Fougera), in Germany, Austria, Switzerland (by Abbott) and Spain (by Bial). Market authorisation has been granted for other countries or is expected within the next few months.

Agreement Information:
Agreement Status: Updated Date Announced: 20 Mar 2013
Date Last Reported: 18 May 2011 Duration:
Est Total Value: Investment To Date:
Agreement Type: Commercialisation
Generic / Brand Name: Veregen sinecatechins
Therapeutic Area: General Anti-infectives Systemic Genito-urinary System and Sex Hormones
Indication: Genital warts
Techonology/Field: N/A
This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Australia, Asia, Australia, New Zealand, Asia, Asia

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.